Nuclera

Cambridge, United Kingdom

Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.

$12.0M raised

Jan 2026

Series C

Top Investors

British Business BankPatient Square CapitalAmadeus Capital PartnersVerve VenturesCambridge Innovation Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Nuclera raised?

Nuclera has raised $12.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.

Who are Nuclera's investors?

Nuclera's investors include British Business Bank, Patient Square Capital, Amadeus Capital Partners, Verve Ventures, Cambridge Innovation Capital.

Where is Nuclera headquartered?

Nuclera is headquartered in Cambridge, United Kingdom.

What does Nuclera do?

Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.

What stage is Nuclera at?

Nuclera is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 13, 2026.

MLA

"Nuclera — Funding & Investors." VCBacked, January 13, 2026, https://www.vcbacked.co/company/nuclera. Accessed June 4, 2026.

APA

VCBacked. (2026). Nuclera — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/nuclera

Wikipedia (cite web)

{{cite web |title=Nuclera — Funding & Investors |url=https://www.vcbacked.co/company/nuclera |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 13, 2026.